SCHEMBL6441907

SCHEMBL6441907

CSc1nc(N)nc(Cl)c1C#N

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.52
HPGD P15428 3/20 0.52
MEN1 O00255 10/20 0.50
KMT2A Q03164 10/20 0.50
MAPT P10636 9/20 0.50
LMNA P02545 5/20 0.50
NPSR1 Q6W5P4 5/20 0.50
HTT P42858 4/20 0.50
PKM P14618 2/20 0.50
MAPK1 P28482 2/20 0.50
TSHR P16473 2/20 0.50
GAA P10253 2/20 0.50
GLA P06280 1/20 0.50
KDM4E B2RXH2 3/20 0.49
CYP1A2 P05177 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
POLB P06746 1/20 0.49
CYP2D6 P10635 1/20 0.49
HSD17B10 Q99714 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL967156 0.86 ALDH1A1 (0.59) ALDH1A1HPGDMEN1KMT2AMAPT
SCHEMBL9640969 0.81 KMT2A (0.53) ALDH1A1HPGDMEN1KMT2AMAPT
SCHEMBL17458364 0.80 ALDH1A1 (0.54) ALDH1A1HPGDMEN1KMT2AMAPT
SCHEMBL15955611 0.79 KMT2A (0.56) ALDH1A1HPGDMEN1KMT2AMAPT
SCHEMBL4417421 0.78 ALDH1A1 (0.49) ALDH1A1HPGDMEN1KMT2AMAPT
SCHEMBL965018 0.78 ALDH1A1 (0.49) ALDH1A1HPGDMEN1KMT2AMAPT
SCHEMBL6250094 0.78 ALDH1A1 (0.52) ALDH1A1HPGDMEN1KMT2AMAPT
SCHEMBL967753 0.76 ALDH1A1 (0.48) ALDH1A1HPGDMEN1KMT2AMAPT
SCHEMBL967859 0.75 ALDH1A1 (0.47) ALDH1A1HPGDMEN1KMT2AMAPT
SCHEMBL6444900 0.75 NPSR1 (0.64) ALDH1A1HPGDMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed
EP-0508353-B1 Process for the preparation of 4-amino-2-chloro-5-cyano-6-(methylthio)pyrimidine LONZA AG (CH) 1996-06-26 EP disclosed
US-5216160-A PROCESS FOR THE PRODUCTION OF 4-AMINO-2-CHLORO-5-CYANO-6-(METHYLTHIO)PYRIMIDINE LONZA LTD. (CH) 1993-06-01 US disclosed
EP-0508353-A1 Process for the preparation of 4-amino-2-chloro-5-cyano-6-(methylthio)pyrimidine LONZA AG (CH) 1992-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ALDH1A1 534/4885HPGD 915/4885MEN1 4860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.